PBCAR-19B by Precision Biosciences for Mantle Cell Lymphoma: Likelihood of Approval
PBCAR-19B is under clinical development by Precision Biosciences and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData, Phase I drugs for Mantle Cell Lymphoma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData's report assesses how PBCAR-19B's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.PBCAR-19B overviewPBCAR-19B is under development for the treatment of relapsed or refractory diffuse large B cell lymphoma and mantle cell lymphoma. The drug candidate comprises T cells expressing chimeric antigen receptor (CAR). It is administered by the intravenous route. It acts by targeting CD19. The drug candidate is being developed using electroporation technologies and ARCUS genome-editing technology. It is a genome editing platform derived from a natural genome editing enzyme called homing endonuclease which incorporates Adeno-associated virus (AAV) vector.Precision Biosciences overviewPrecision Biosciences is a biotechnology company, that develops and commercializes gene therapy and cancer immunotherapy. The company intends to its ARCUS technology, a proprietary genome editing platform, which combines specificity and efficacy, on the development of food, fuel and feed-based products. Precision BioSciences ARCUS technology helps improve genes related to crop quality, yield, and performance traits and strives to advance food products. The company also applies its ARCUS technology to the development of cell-based immunotherapies to cure genetic diseases. Precision BioSciences genome editing platform is derived from a natural genome editing enzyme, homing endonuclease. The company partners with various pharmaceutical and biotech companies to develop novel therapies for the treatment of cancer. Precision BioSciences is headquartered in Durham, North Carolina, the US. For a complete picture of PBCAR-19B's drug-specific PTSR and LoA scores, buy the report here.
PBCAR-19B is under clinical development by Precision Biosciences and currently in Phase I for Mantle Cell Lymphoma.
What's Your Reaction?
